Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Larry Norton

Showing results (171-180 of 293) with videos related to

Pageof 30
Sort By:
Cancer Research|October 18, 2017
An Akt3 Splice Variant Lacking the Serine 472 Phosphorylation Site Promotes Apoptosis and Suppresses Mammary TumorigenesisKimita Suyama, Jiahong Yao, Huizhi Liang, et al.
Breast Cancer Research and Treatment|June 15, 2006
Interleukin-6, multidrug resistance protein-1 expression and response to paclitaxel in women with metastatic breast cancer: results of cancer and leukemia group B trial 159806Mercedes Rincon, Gloria Broadwater, Lyndsay Harris, et al.
Journal of the National Cancer Institute|October 16, 2003
Shared genetic susceptibility to breast cancer, brain tumors, and Fanconi anemiaKenneth Offit, Orna Levran, Brian Mullaney, et al.
Iscience|February 9, 2024
Preoperative immune checkpoint inhibition and cryoablation in early-stage breast cancerElizabeth Comen, Sadna Budhu, Yuval Elhanati, et al.
The New England Journal of Medicine|May 25, 2002
Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutationNoah D Kauff, Jaya M Satagopan, Mark E Robson, et al.
NPJ Breast Cancer|October 18, 2024
Predictors of response to CDK4/6i retrial after prior CDK4/6i failure in ER+ metastatic breast cancerNicholas Mai, Carlos H Dos Anjos, Pedram Razavi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2007
Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation studyShanu Modi, Alison T Stopeck, Michael S Gordon, et al.
Research Square|May 15, 2024
Predictors of Response to CDK4/6i Retrial After Prior CDK4/6i Failure in ER+ Metastatic Breast CancerNicholas Mai, Carlos H Dos Anjos, Pedram Razavi, et al.
Clinical Breast Cancer|April 23, 2018
Phase II Study of Paclitaxel and Dasatinib in Metastatic Breast CancerPatrick G Morris, Selene Rota, Karen Cadoo, et al.
Journal of the National Cancer Institute|September 11, 2019
Evaluating Clonal Hematopoiesis in Tumor-Infiltrating Leukocytes in Breast Cancer and Secondary Hematologic MalignanciesElizabeth A Comen, Robert L Bowman, Pier Selenica, et al.
Pageof 30

Showing results (171-180 of 293) with videos related to

Sort By:
Pageof 30
Cancer Research|October 18, 2017
An Akt3 Splice Variant Lacking the Serine 472 Phosphorylation Site Promotes Apoptosis and Suppresses Mammary TumorigenesisKimita Suyama, Jiahong Yao, Huizhi Liang, et al.
Breast Cancer Research and Treatment|June 15, 2006
Interleukin-6, multidrug resistance protein-1 expression and response to paclitaxel in women with metastatic breast cancer: results of cancer and leukemia group B trial 159806Mercedes Rincon, Gloria Broadwater, Lyndsay Harris, et al.
Journal of the National Cancer Institute|October 16, 2003
Shared genetic susceptibility to breast cancer, brain tumors, and Fanconi anemiaKenneth Offit, Orna Levran, Brian Mullaney, et al.
Iscience|February 9, 2024
Preoperative immune checkpoint inhibition and cryoablation in early-stage breast cancerElizabeth Comen, Sadna Budhu, Yuval Elhanati, et al.
The New England Journal of Medicine|May 25, 2002
Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutationNoah D Kauff, Jaya M Satagopan, Mark E Robson, et al.
NPJ Breast Cancer|October 18, 2024
Predictors of response to CDK4/6i retrial after prior CDK4/6i failure in ER+ metastatic breast cancerNicholas Mai, Carlos H Dos Anjos, Pedram Razavi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2007
Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation studyShanu Modi, Alison T Stopeck, Michael S Gordon, et al.
Research Square|May 15, 2024
Predictors of Response to CDK4/6i Retrial After Prior CDK4/6i Failure in ER+ Metastatic Breast CancerNicholas Mai, Carlos H Dos Anjos, Pedram Razavi, et al.
Clinical Breast Cancer|April 23, 2018
Phase II Study of Paclitaxel and Dasatinib in Metastatic Breast CancerPatrick G Morris, Selene Rota, Karen Cadoo, et al.
Journal of the National Cancer Institute|September 11, 2019
Evaluating Clonal Hematopoiesis in Tumor-Infiltrating Leukocytes in Breast Cancer and Secondary Hematologic MalignanciesElizabeth A Comen, Robert L Bowman, Pier Selenica, et al.
Pageof 30